Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts

Biomaterials

Volumn 32, Issue 25, 2011, Pages 5872-5879

  Zhang, Rui ^a   Xiong, Chiyi ^a   Huang, Miao ^a   Zhou, Min ^a   Huang, Qian ^a   Wen, Xiaoxia ^a   Liang, Dong ^b   Li, Chun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

Fluorescence; Micelle; Molecular imaging; Nanoparticle

Indexed keywords

BINDING PEPTIDE; CANCER CELLS; CO-INJECTION; EARLY DETECTION; FLUORESCENCE SIGNALS; IMMUNOHISTOCHEMICAL ANALYSIS; IN-VITRO; IN-VIVO; INTRAVENOUS ADMINISTRATION; LUNG CANCER CELLS; MICELLAR NANOPARTICLES; MOLECULAR IMAGING; MULTI-MODAL; NEAR-INFRARED FLUORESCENCE; NEAR-INFRARED FLUORESCENCE IMAGING; OPTICAL IMAGING; OPTICAL TECHNIQUE; POLYMERIC MICELLE; PROSTATE CANCER CELLS; PROSTATE CANCERS; RADIOACTIVITY COUNTS; RECEPTOR TYROSINE KINASE;

AMINO ACIDS; CELLS; DISEASES; FLUORESCENCE; FLUOROPHORES; GLYCOLS; INFRARED DEVICES; MICELLES; NANOPARTICLES; NUCLEAR MEDICINE; PEPTIDES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TOMOGRAPHY; TUMORS; VISUALIZATION;

SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

CORE CROSSLINKED POLYMERIC MICELLE; EPHRIN RECEPTOR B4; INDIUM 111; MACROGOL; NANOPARTICLE; PEPTIDE DERIVATIVE; THREONYLASPARAGINYLTYROSYLLEUCYLPHENYLALANYLSERYLPROLYLASPARAGINYLGLYCYLPROLYLISOLEUCYLALANYLARGINYLALANYLTRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONJUGATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BINDING; DRUG DISTRIBUTION; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFRARED RADIATION; LABELING INDEX; LUNG CANCER; MALE; MICELLE; MOUSE; NONHUMAN; OPTICS; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

CELL LINE, TUMOR; HUMANS; MALE; MICELLES; NANOPARTICLES; PEPTIDES; POLYMERS; PROSTATIC NEOPLASMS; RECEPTOR, EPHB4; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 79957918283     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.04.070     Document Type: Article

References (33)

1. Pasquale E.B. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005, 6:462-475.
2. Dodelet V.C., Pasquale E.B. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 2000, 19:5614-5619.
3. Nakamoto M., Bergemann A.D. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 2002, 59:58-67.
4. Koolpe M., Burgess R., Dail M., Pasquale E.B. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem 2005, 280:17301-17311.
5. Walker-Daniels J., Hess A.R., Hendrix M.J., Kinch M.S. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 2003, 162:1037-1042.
6. Brantley-Sieders D.M., Caughron J., Hicks D., Pozzi A., Ruiz J.C., Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 2004, 117:2037-2049.
7. Noren N.K., Lu M., Freeman A.L., Koolpe M., Pasquale E.B. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A 2004, 101:5583-5588.
8. Battaglia A.A., Sehayek K., Grist J., McMahon S.B., Gavazzi I. EphB receptors and ephrin-B ligands regulate spinal sensory connectivity and modulate pain processing. Nat Neurosci 2003, 6:339-340.
9. Goldshmit Y., Galea M.P., Wise G., Bartlett P.F., Turnley A.M. Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice. J Neurosci 2004, 24:10064-10073.
10. Xia G., Kumar S.P., Stein J.P., Singh J., Krasnoperov V., Zhu S., et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 2006, 25:769-780.
11. Erber R., Eichelsbacher U., Powajbo V., Korn T., Djonov V., Lin J.H., et al. EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J 2006, 25:628-641.
12. Kumar S.R., Scehnet J.S., Ley E.J., Singh J., Krasnoperov V., Liu R., et al. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 2009, 69:3736-3745.
13. Kumar S.R., Singh J., Xia G.B., Krasnoperov V., Hassanieh L., Ley E.J., et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006, 169:279-293.
14. Xiong C., Huang M., Zhang R., Song S., Lu W., Flores L., et al. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide. J Nucl Med 2011, 52:241-248.
15. Yang Z., Zheng S., Harrison W.J., Harder J., Wen X., Gelovani J.G., et al. Long-circulating near-infrared fluorescence core-cross-linked polymeric micelles: synthesis, characterization, and dual nuclear/optical imaging. Biomacromolecules 2007, 8:3422-3428.
16. Munoz-Torrero D. Exploiting multivalency in drug design. Curr Pharm Des 2009, 15:585-586.
17. Deyev S.M., Lebedenko E.N. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Bioessays 2008, 30:904-918.
18. Vadas O., Rose K. Multivalency - a way to enhance binding avidities and bioactivity-preliminary applications to EPO. J Pept Sci 2007, 13:581-587.
19. Baudino L., Fossati-Jimack L., Chevalley C., Martinez-Soria E., Shulman M.J., Izui S. IgM and IgA anti-erythrocyte autoantibodies induce anemia in a mouse model through multivalency-dependent hemagglutination but not through complement activation. Blood 2007, 109:5355-5362.
20. Wang J., Tian S.M., Petros R.A., Napier M.E., DeSimone J.M. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J Am Chem Soc 2010, 132:11306-11313.
21. Chiu G.N.C., Edwards L.A., Kapanen A.I., Malinen M.M., Dragowska W.H., Warburton C., et al. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther 2007, 6:844-855.
22. Cai W.B., Shin D.W., Chen K., Gheysens O., Cao Q.Z., Wang S.X., et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006, 6:669-676.
23. Devaraj N.K., Keliher E.J., Thurber G.M., Nahrendorf M., Weissleder R. F-18 labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem 2009, 20:397-401.
24. Patel D., Kell A., Simard B., Deng J.X., Xiang B., Lin H.Y., et al. Cu2+-labeled, SPION loaded porous silica nanoparticles for cell labeling and multifunctional imaging probes. Biomaterials 2010, 31:2866-2873.
25. Wu W.T., Aiello M., Zhou T., Berliner A., Banerjee P., Zhou S.Q. In-situ immobilization of quantum dots in polysaccharide-based nanogels for integration of optical pH-sensing, tumor cell imaging, and drug delivery. Biomaterials 2010, 31:3023-3031.
26. Welch M.J., Hawker C.J., Wooley K.L. The advantages of nanoparticles for PET. J Nucl Med 2009, 50:1743-1746.
27. Yang J., Lim E.K., Lee H.J., Park J., Lee S.C., Lee K., et al. Fluorescent magnetic nanohybrids as multimodal imaging agents for human epithelial cancer detection. Biomaterials 2008, 29:2548-2555.
28. Yu X.F., Sun Z.B., Li M., Xiang Y., Wang Q.Q., Tang F.F., et al. Neurotoxin-conjugated upconversion nanoprobes for direct visualization of tumors under near-infrared irradiation. Biomaterials 2010, 31:8724-8731.
29. Zhou M., Zhang R., Huang M.A., Lu W., Song S.L., Melancon M.P., et al. A chelator-free multifunctional [Cu-64]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy. J Am Chem Soc 2010, 132:15351-15358.
30. Cai W.B., Chen X.Y. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008, 49:113s-128s.
31. Chen K., Li Z.B., Wang H., Cai W.B., Chen X.Y. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 2008, 35:2235-2244.
32. Xie J., Chen K., Huang J., Lee S., Wang J.H., Gao J., et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 2010, 31:3016-3022.
33. Nahrendorf M., Keliher E., Marinelli B., Waterman P., Feruglio P.F., Fexon L., et al. Hybrid PET-optical imaging using targeted probes. Proc Natl Acad Sci U S A 2010, 107:7910-7915.